MKGAY News and Press, Merck KGaA ADR From 12/09/19

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

A Phase 3 clinical trial, JAVELIN Gastric 100 , evaluating Pfizer (NYSE: PFE ) and alliance partner Merck KGaA's ( OTCPK:MKGAY ) Bavencio (avelumab) as first-line maintenance therapy following induction chemotherapy in patients with unresectable, locally advanced or metastatic HER2-negative...

Pfizer ( PFE +1.3% ) and alliance partner EMD Serono ( OTCPK:MKGAY ) announce European Commission approval of Bavencio (avelumab), combined with Inlyta (axitinib), for the first-line treatment of adult patients with advanced renal cell carcinoma. More news on: Pfizer Inc., Merck KGaA A...

Deals and Financings Ascentage Pharma of Suzhou completed a $53 million Hong Kong IPO, pricing the offering at the top end of the indicated range with a market capitalization of almost $890 million. The company is developing therapeutics for cancer based on its expertise in protein-protein i...

Merger activity remained unchanged last week with two new deals announced and seven deals closing. Deal Statistics: New Deals: The acquisition of Alder BioPharmaceuticals (ALDR) by H. Lundbeck A/S for $1.95 billion. Under the terms of the agreement, Alder stockholders will be of...

Noteworthy events during the week of September 8 - 14 for healthcare investors. More news on: Alnylam Pharmaceuticals, Inc., Johnson & Johnson, Xeris Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Vaccinex ( VCNX -1.5% ) announces  full enrollment (n=62) in a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating lead candidate pepinemab (VX15/2503), combined with Pfizer's ( PFE +0.6% ) Bavencio (avelumab), in patients with advanced non-small cell lung cancer (NSCLC). Mor...

Merck KGaA ( MKKGY ) (MKGAY) and its partner Pfizer ( PFE ) announced that they had obtained FDA approval for their drug Bavencio to treat first-line advanced kidney cancer. This is good news because the PD-1/PD-L1 inhibitor will finally have the shot at another market. Bavencio has struggle...

Updated results from a Phase 2 clinical trial evaluating Merck KGaA's ( OTCPK:MKGAY ) evobrutinib (formerly designated as M2951) in patients with relapsing multiple sclerosis (MS) showed a sustained treatment benefit. The data were presented at the American Academy of Neurology Annual M...

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...